Moderna Reports First Quarter 2022 Financial Results and Provides Business Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Wolfe Research Continues to Favor Moderna's (MRNA) 'Significiant Upside Optionality' in its Broad Pipeline
May 4, 2022 10:22 AM EDTWolfe Research analyst Andrew Galler reiterated an Outperform rating and $261.00 price target on Moderna (NASDAQ: MRNA).
The analyst comments "At the time of our initiation in November 2021, the stock was coming off of a onetwo punch from a cut to COVID vaccine guidance and PFEs topline data for Paxlovid from the EPIC-HR study, but with increasing visibility into the booster opportunity (which has only been helped by the spread of the Omicron variant), the... More
Moderna (MRNA) Tops Q1 EPS by $3.37, Revenue Beats
May 4, 2022 6:54 AM EDTModerna (NASDAQ: MRNA) reported Q1 EPS of $8.58, $3.37 better than the analyst estimate of $5.21. Revenue for the quarter came in at $6.1 billion versus the consensus estimate of $4.62 billion.
For earnings history and earnings-related data on Moderna (MRNA) click here.
... More